LIFE aTYR PHARMA INC

  1. Stocks
  2. Healthcare
  3. NASDAQ: LIFE

Price (delayed)

$1.57

Market cap

$106.37M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.94

Enterprise value

$95.43M

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered ...

Highlights
LIFE's EPS is up by 41% year-on-year and by 3.1% since the previous quarter
The company's equity rose by 27% YoY but it fell by 8% QoQ
aTYR PHARMA's quick ratio has decreased by 24% from the previous quarter but it has increased by 8% YoY
The revenue has shrunk by 97% QoQ and by 97% YoY
The company's gross profit has shrunk by 97% QoQ and by 97% YoY
Sector: Healthcare
Industry: Biotechnology
Website: https://www.atyrpharma.com/
Peers: VRTX ADXS KPTI VSTM

Key stats

What are the main financial stats of LIFE
Market
Shares outstanding
67.75M
Market cap
$106.37M
Enterprise value
$95.43M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.01
Price to sales (P/S)
238.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
270.35
Earnings
Revenue
$353,000
EBIT
-$50.39M
EBITDA
-$47.65M
Free cash flow
-$37.42M
Per share
EPS
-$0.94
Free cash flow per share
-$0.7
Book value per share
$1.55
Revenue per share
$0.01
TBVPS
$2.25
Balance sheet
Total assets
$120.65M
Total liabilities
$30.18M
Debt
$15.1M
Equity
$90.66M
Working capital
$86.58M
Liquidity
Debt to equity
0.17
Current ratio
6.27
Quick ratio
6.34
Net debt/EBITDA
0.23
Margins
EBITDA margin
-13,498%
Gross margin
100%
Net margin
-14,274.5%
Operating margin
-15,557.8%
Efficiency
Return on assets
-39.1%
Return on equity
-49.7%
Return on invested capital
-45.7%
Return on capital employed
-48.3%
Return on sales
-14,274.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LIFE stock price

How has the aTYR PHARMA stock price performed over time
Intraday
-1.88%
1 week
-3.09%
1 month
-19.49%
1 year
-19.49%
YTD
11.35%
QTD
-19.49%

Financial performance

How have aTYR PHARMA's revenue and profit performed over time
Revenue
$353,000
Gross profit
$353,000
Operating income
-$54.92M
Net income
-$50.39M
Gross margin
100%
Net margin
-14,274.5%
The revenue has shrunk by 97% QoQ and by 97% YoY
The company's gross profit has shrunk by 97% QoQ and by 97% YoY
aTYR PHARMA's operating income has decreased by 18% YoY and by 17% from the previous quarter
The net income has contracted by 17% from the previous quarter and by 11% YoY

Growth

What is aTYR PHARMA's growth rate over time

Valuation

What is aTYR PHARMA stock price valuation
P/E
N/A
P/B
1.01
P/S
238.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
270.35
LIFE's EPS is up by 41% year-on-year and by 3.1% since the previous quarter
The company's equity rose by 27% YoY but it fell by 8% QoQ
LIFE's P/B is 8% below its 5-year quarterly average of 1.1
The revenue has shrunk by 97% QoQ and by 97% YoY

Efficiency

How efficient is aTYR PHARMA business performance
The company's return on invested capital rose by 19% YoY but it fell by 13% QoQ
The ROA has grown by 15% YoY but it has contracted by 11% from the previous quarter
The return on equity has declined by 11% since the previous quarter but it is up by 8% year-on-year

Dividends

What is LIFE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LIFE.

Financial health

How did aTYR PHARMA financials performed over time
The total assets has grown by 26% YoY but it has contracted by 3.5% from the previous quarter
The current ratio has contracted by 25% from the previous quarter but it has grown by 8% YoY
The debt is 83% less than the equity
The debt has grown by 31% YoY
The company's equity rose by 27% YoY but it fell by 8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.